Article
Pharmacology & Pharmacy
Haiyan Liu, Ziping Li, Fei Qiu, Chunjie Li, Xiaojing Lin, Yingyi He, Maoxiang Qian, Yuanbin Song, Hui Zhang
Summary: This study investigated the association between NR3C1 gene mutations and treatment outcomes in pediatric acute lymphoblastic leukemia (ALL), finding that NR3C1 mutations are associated with glucocorticoid resistance. Loss-of-function (LoF) NR3C1 mutations influence GC resistance, indicating that NR3C1 alterations play a critical role in GC resistance and may contribute to treatment failure and relapse in ALL.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Wohn-Jenn Leu, Hsun-Shuo Chang, Ih-Sheng Chen, Jih-Hwa Guh, She-Hung Chan
Summary: Ardisianone induces apoptosis and differentiation of leukemic cells through upregulation of death receptors, activation of caspase pathways, and downregulation of inhibitors of apoptosis proteins, suggesting its potential for antileukemic development.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Yan Mao, Jinwen Xu, Xuejiao Xu, Jiayun Qiu, Zhengyun Hu, Feng Jiang, Guoping Zhou
Summary: Cellular senescence plays a critical role in carcinogenesis, development, and immunological regulation. This study identified a cellular senescence-related gene signature that can serve as a reliable predictor for clinical outcome and immunotherapeutic response in patients with acute myeloid leukemia.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Tatsushi Yoshida, Kenta Yamasaki, Kenjiro Tadagaki, Yasumichi Kuwahara, Akifumi Matsumoto, Adem Ejub Sofovic, Noriko Kondo, Toshiyuki Sakai, Tsukasa Okuda
Summary: The study identified RUNX1 as a transcriptional regulator of TRAIL, showing that TRAIL expression is decreased in acute myeloid leukemia patients and inhibited by RUNX1-ETO.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Fei Kong, Huiyuan Bai, Ming Ma, Chen Wang, Haiyan Xu, Ning Gu, Yu Zhang
Summary: The utilization of a composite nanozyme to target and treat acute myeloid leukemia represents a potential therapeutic approach, alleviating the toxic side effects of chemotherapy and improving treatment efficacy.
Article
Multidisciplinary Sciences
Daniel J. Lightwood, Rebecca J. Munro, John Porter, David McMillan, Bruce Carrington, Alison Turner, Anthony Scott-Tucker, Elizabeth S. Hickford, Antje Schmidt, David Fox, Alison Maloney, Tom Ceska, Tim Bourne, James O'Connell, Alastair D. G. Lawson
Summary: TNF can be inhibited by small molecules that stabilize the TNF trimer in an asymmetric conformation. The authors also developed a monoclonal antibody that selectively binds this inactive form of TNF, enabling both target engagement assessment and structural characterization of TNF binding to TNF receptor 1.
NATURE COMMUNICATIONS
(2021)
Review
Immunology
Lorena Perez-Amill, Alex Bataller, Julio Delgado, Jordi Esteve, Manel Juan, Nela Klein-Gonzalez
Summary: This article provides guidance for the design, development, and clinical translation of CAR-T cell therapies for AML treatment. It discusses the considerations in designing these therapies, in vitro and in vivo assays to prove their efficacy and safety, and the expertise and facilities required for treating and managing patients in the hospital.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Desiree Kunadt, Friedrich Stoelzel
Summary: The number of patients receiving allogeneic hematopoietic stem cell transplantation (alloHCT) has been increasing due to advances in transplant technology, supportive care, transplant safety, and donor availability. Acute myeloid leukemia (AML) is the most common indication for alloHCT, but disease relapse remains a major challenge. Maintaining a strong graft-versus-leukemia (GvL) effect is crucial for patient prognosis and long-term survival.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Vincent Marmouset, Justine Decroocq, Sylvain Garciaz, Gabriel Etienne, Amine Belhabri, Sarah Bertoli, Lauris Gastaud, Celestine Simand, Sylvain Chantepie, Madalina Uzunov, Alexis Genthon, Celine Berthon, Edmond Chiche, Pierre-Yves Dumas, Jacques Vargaftig, Geraldine Salmeron, Emilie Lemasle, Emmanuelle Tavernier, Jeremy Delage, Marion Loirat, Nadine Morineau, Felix Blanc-Durand, Patricia Pautier, Veronique Verge, Nathalie Auger, Myrtille Thomas, Laetitia Stefani, Marion Lepelley, Thomas Boyer, Sylvain Thepot, Marie-Pierre Gourin, Pascal Bourquard, Matthieu Duchmann, Pierre-Marie Morice, Mauricette Michallet, Lionel Ades, Pierre Fenaux, Christian Recher, Herve Dombret, Arnaud Pages, Christophe Marzac, Alexandra Leary, Jean-Baptiste Micol
Summary: This study provides insights into the diagnosis and management of therapy-related myeloid neoplasms (t-MN) following PARP inhibitors (PARPi). The study found a high incidence of t-MN post-PARPi among patients with ovarian cancer, which is associated with unfavorable cytogenetic and molecular abnormalities leading to poor overall survival.
CLINICAL CANCER RESEARCH
(2022)
Article
Immunology
Yu Zhang, Chenjing Ye, Haojie Zhu, Youran Zhuang, Shaozhen Chen, Yingxi Weng, Jinhua Ren, Xiaofeng Luo, Jing Zheng, Xiaoyun Zheng, Jing Li, Lingqiong Lan, Yongxin Xie, Zhongchao Han, Jianda Hu, Ting Yang
Summary: This study investigated the impact of KIR mismatch and KIR alleles on haplo-HSCT outcome in AML patients. The results showed that both KIR ligand mismatch (KLM) and KIR receptor-ligand mismatch (RLM) were associated with a decreased risk of aGVHD and relapse, as well as better overall survival. RLM was more accurate in predicting HSCT outcome than KLM. Patients with a higher number of donor activating KIRs (aKIR) had a lower incidence of aGVHD and relapse. RLM and a high number of donor aKIRs together provided a better donor selection strategy for improving haplo-HSCT outcome in AML patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Genetics & Heredity
Guangcai Zhong, Chong Guo, Yangli Shang, Zelong Cui, Minran Zhou, Mingshan Sun, Yue Fu, Lu Zhang, Huimin Feng, Chunyan Chen
Summary: In this study, a PRlncRNA signature was constructed and found to be an accurate predictor of prognosis in AML. The high-risk group showed differences in immune infiltration, enrichment analysis, and drug sensitivity.
FRONTIERS IN GENETICS
(2023)
Review
Pathology
Sabine Dieleman, Romy Aarnoutse, Janine Ziemons, Loes Kooreman, Annemarie Boleij, Marjolein Smidt
Summary: Breast cancer tissue has its own unique microbiota which can influence cancer initiation and progression, serving as a potential biomarker for treatment and prognosis. Variations in breast microbiota composition among cancer subtypes and disease severities may contribute to immunosuppression and evasion of immune destruction by tumor cells. The interactions between breast microbiota, gut microbiota, and the immune system offer potential targets for improving therapeutic efficacy.
AMERICAN JOURNAL OF PATHOLOGY
(2021)
Review
Immunology
Michela Luciano, Peter W. Krenn, Jutta Horejs-Hoeck
Summary: Acute myeloid leukemia (AML) is a heterogeneous blood cancer with complex disease characteristics and cytokine networks, making treatment challenging. The development of new targeted therapies and understanding the functions of cytokines are important for improving treatment options.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Valentina Palmerini, Silvia Monzani, Quentin Laurichesse, Rihab Loudhaief, Sara Mari, Valentina Cecatiello, Vincent Olieric, Sebastiano Pasqualato, Julien Colombani, Ditte S. Andersen, Marina Mapelli
Summary: The Drosophila tumour necrosis factor (TNF) system consists of a single ligand, Eiger (Egr), and two receptors. The crystallographic structure of Egr in complex with the extracellular domain of the receptor Grindelwald suggests that distinct affinities of TNF ligand for its receptors mediate non-redundant functions.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Enrico Kittel-Boselli, Karla Elizabeth Gonzalez Soto, Liliana Rodrigues Loureiro, Anja Hoffmann, Ralf Bergmann, Claudia Arndt, Stefanie Koristka, Nicola Mitwasi, Alexandra Kegler, Tabea Bartsch, Nicole Berndt, Heidi Altmann, Frederick Fasslrinner, Martin Bornhaeuser, Michael Philipp Bachmann, Anja Feldmann
Summary: Clinical translation of novel immunotherapeutic strategies, such as CAR T-cells in AML, is still in its early stages, with challenges including immune escape and disease relapse. The development of the RevCAR platform provides a new approach to overcome these challenges and enables efficient killing of AML cells through combinatorial tumor targeting using Boolean logic gates. These achievements pave the way for improved and personalized immunotherapy for AML patients.
Article
Oncology
J. Wild, B. J. Schmiedel, A. Maurer, S. Raab, L. Prokop, S. Stevanovic, D. Doerfel, P. Schneider, H. R. Salih
Article
Multidisciplinary Sciences
Benjamin Joachim Schmiedel, Gregory Seumois, Daniela Samaniego-Castruita, Justin Cayford, Veronique Schulten, Lukas Chavez, Ferhat Ay, Alessandro Sette, Bjoern Peters, Pandurangan Vijayanand
NATURE COMMUNICATIONS
(2016)
Article
Oncology
Sebastian P. Haen, Benjamin J. Schmiedel, Kathrin Rothfelder, Bastian J. Schmied, Truong-Minh Dang, Nora Mirza, Robert Moehle, Lothar Kanz, Wichard Vogel, Helmut R. Salih
Article
Oncology
Tina Nuebling, Carla Emilia Schumacher, Martin Hofmann, Ilona Hagelstein, Benjamin Joachim Schmiedel, Stefanie Maurer, Birgit Federmann, Kathrin Rothfelder, Malte Roerden, Daniela Doerfel, Pascal Schneider, Gundram Jung, Helmut Rainer Salih
CANCER IMMUNOLOGY RESEARCH
(2018)
Article
Oncology
Julia Steinbacher, Katrin Baltz-Ghahremanpour, Benjamin Joachim Schmiedel, Alexander Steinle, Gundram Jung, Ayline Kuebler, Maya Caroline Andre, Ludger Grosse-Hovest, Helmut Rainer Salih
INTERNATIONAL JOURNAL OF CANCER
(2015)
Article
Biochemistry & Molecular Biology
Benjamin J. Schmiedel, Divya Singh, Ariel Madrigal, Alan G. Valdovino-Gonzalez, Brandie M. White, Jose Zapardiel-Gonzalo, Brendan Ha, Gokmen Altay, Jason A. Greenbaum, Graham McVicker, Gregory Seumois, Anjana Rao, Mitchell Kronenberg, Bjoern Peters, Pandurangan Vijayanand
Article
Medicine, Research & Experimental
Mattias N. D. Svensson, Karen M. Doody, Benjamin J. Schmiedel, Sourya Bhattacharyya, Bharat Panwar, Florian Wiede, Shen Yang, Eugenio Santelli, Dennis J. Wu, Cristiano Sacchetti, Ravindra Gujar, Gregory Seumois, William B. Kiosses, Isabelle Aubry, Gisen Kim, Piotr Mydel, Shimon Sakaguchi, Mitchell Kronenberg, Tony Tiganis, Michel L. Tremblay, Ferhat Ay, Pandurangan Vijayanand, Nunzio Bottini
JOURNAL OF CLINICAL INVESTIGATION
(2019)
Article
Immunology
Gregory Seumois, Ciro Ramirez-Suastegui, Benjamin J. Schmiedel, Shu Liang, Bjoern Peters, Alessandro Sette, Pandurangan Vijayanand
SCIENCE IMMUNOLOGY
(2020)
Article
Multidisciplinary Sciences
Justin Cayford, Sara Herrera-la Mata, Benjamin Joachim Schmiedel, Vivek Chandra, Pandurangan Vijayanad, Gregory Seumois
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
(2020)
Article
Genetics & Heredity
Vivek Chandra, Sourya Bhattacharyya, Benjamin J. Schmiedel, Ariel Madrigal, Cristian Gonzalez-Colin, Stephanie Fotsing, Austin Crinklaw, Gregory Seumois, Pejman Mohammadi, Mitchell Kronenberg, Bjoern Peters, Ferhat Ay, Pandurangan Vijayanand
Summary: This study utilized H3K27ac HiChIP analysis to identify promoter-interacting expression quantitative trait loci (pieQTLs) in five common immune cell types, showing the importance of these variants in gene regulation. Additionally, the study presents a method for functional eQTL discovery and provides insights into the relevance of noncoding variants for cell-specific gene regulation and disease association.
Article
Biochemistry & Molecular Biology
Bharat Panwar, Benjamin J. Schmiedel, Shu Liang, Brandie White, Enrique Rodriguez, Kenneth Kalunian, Andrew J. McKnight, Rachel Soloff, Gregory Seumois, Pandurangan Vijayanand, Ferhat Ay
Summary: Systemic lupus erythematosus (SLE) is an incurable autoimmune disease that predominantly affects women. Research has shown that the presence of interferon response signature stratifies SLE patients into two distinct groups, and identified certain genes associated with disease severity.
Article
Multidisciplinary Sciences
Benjamin J. Schmiedel, Vivek Chandra, Job Rocha, Cristian Gonzalez-Colin, Sourya Bhattacharyya, Ariel Madrigal, Christian H. Ottensmeier, Ferhat Ay, Pandurangan Vijayanand
Summary: The study assessed the effects of COVID-19-risk variants on gene expression in various immune cell types, highlighting their potential impact on immune cell function and severe disease. Through transcriptome-wide association study and colocalization analysis, specific immune cell types and putative causal genes influenced by COVID-19-risk variants were identified.
NATURE COMMUNICATIONS
(2021)
Article
Immunology
Benjamin J. Schmiedel, Cristian Gonzalez-Colin, Vicente Fajardo, Job Rocha, Ariel Madrigal, Ciro Ramirez-Suastegui, Sourya Bhattacharyya, Hayley Simon, Jason A. Greenbaum, Bjoern Peters, Gregory Seumois, Ferhat Ay, Vivek Chandra, Pandurangan Vijayanand
Summary: This study reveals the specific effects of common genetic variants on gene expression in CD4(+)T cells, with these effects being most prominent in certain cell types. The study also identifies new gene associations for disease-risk variants and highlights the influence of biological sex on gene expression in CD4(+)T cell subsets.
SCIENCE IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Meghana Pagadala, Timothy J. Sears, Victoria H. Wu, Eva Perez-Guijarro, Hyo Kim, Andrea Castro, James V. Talwar, Cristian Gonzalez-Colin, Steven Cao, Benjamin J. Schmiedel, Shervin Goudarzi, Divya Kirani, Jessica Au, Tongwu Zhang, Teresa Landi, Rany M. Salem, Gerald P. Morris, Olivier Harismendy, Sandip Pravin Patel, Ludmil B. Alexandrov, Jill P. Mesirov, Maurizio Zanetti, Chi-Ping Day, Chun Chieh Fan, Wesley K. Thompson, Glenn Merlino, J. Silvio Gutkind, Pandurangan Vijayanand, Hannah Carter
Summary: Understanding how host genetics affects the tumor immune microenvironment (TIME) is essential for personalized cancer screening and treatment strategies. A study analyzed the eQTLs affecting TIME and found that they are enriched in areas of active transcription and associated with gene expression in specific immune cell subsets. Polygenic score models built with TIME eQTLs can stratify cancer risk, survival, and immune checkpoint blockade (ICB) response. Inhibiting the CTSS gene, which is implicated by the polygenic models, slows tumor growth and extends survival, suggesting the potential of integrating genetic factors and TIME characteristics for immunotherapy targets.
NATURE COMMUNICATIONS
(2023)
Article
Immunology
Veena S. Patil, Ariel Madrigal, Benjamin J. Schmiedel, James Clarke, Patrick O'Rourke, Aruna D. de Silva, Eva Harris, Bjoern Peters, Gregory Seumois, Daniela Weiskopf, Alessandro Sette, Pandurangan Vijayanand
SCIENCE IMMUNOLOGY
(2018)